

PATENT
ATTORNEY DOCKET NO. 50120/008001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Young, et al. Art Unit: 1635
Serial No.: 10/585,772 Examiner:
371 (c) Date: November 13, 2007 Customer No.: 21559
Title: Antisense Oligonucleotides Directed To Ribonucleotide Reductase
R2 and Uses Thereof In Combination Therapies For The Treatment
Of Cancer

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION FOR A REFUND UNDER 37 C.F.R. § 1.28 (a)

Applicant, as a small entity, petitions herewith for a refund based on small entity status for the above-referenced application since its date of filing.

Applicant claims small entity status under 37 C.F.R. § 1.27(c).

The requested refund is as follows:

<u>Type of Fee</u>	<u>Large entity fee paid</u>	<u>Small entity fee</u>	<u>Refund</u>
Filing Fee	\$ 2250.00	\$1125.00	\$1125.00


This payment was made on July 12, 2006. The total refund requested is \$1125.00.

Please apply this amount to Deposit Account No. 03-2095.

Respectfully submitted,


Date:

August 5, 2008


Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

IAP15 Rec'd PCT/PTO 12 JUL 2006

Certificate of Mailing		
Date of Deposit: <u>July 12, 2006</u>		Label Number: <u>EV 768765377US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		
<u>Elvis De La Cruz</u>		
Printed name of person mailing correspondence		Signature of person mailing correspondence
Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number: <u>50120/008001</u>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. § 371		U.S. Application Number: 10/385772
INTERNATIONAL APPLICATION NUMBER	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/CA05/00040	January 12, 2005	January 12, 2004
TITLE OF INVENTION:	ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCATASE R2 AND USES THEREOF IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER	
APPLICANTS FOR DO/EO/US:	Aiping H. YOUNG, Jim A. WRIGHT, and Yoon LEE	
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.	
2.	<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371.	
3.	<input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. § 371(f)).	
4.	<input checked="" type="checkbox"/> The U.S. has been elected.	
5.	A copy of the International Application (35 U.S.C. § 371(c)(2)). <input checked="" type="checkbox"/> a. is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. has been transmitted by the International Bureau. <input type="checkbox"/> c. is not required, as the application was filed with the United States Receiving Office (RO/US).	
6.	An English language translation of the International Application into English (35 U.S.C. § 371(c)(2)). <input type="checkbox"/> a. is transmitted herewith. <input type="checkbox"/> b. has been previously submitted under 35 U.S.C. 154(d)(4).	
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)). <input type="checkbox"/> a. are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. have been transmitted by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> d. have not been made and will not be made.	
8.	<input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)).	
9.	<input checked="" type="checkbox"/> An oath or declaration of the inventors (35 U.S.C. § 371(c)(4)). (unsigned)	
10.	<input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371 (c)(5)).	
11.	<input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98.	
12.	<input type="checkbox"/> An assignment for recording. A separate cover sheet in compliance with 37 C.F.R. §§ 3.28 and 3.31 is included.	
13.	<input checked="" type="checkbox"/> A preliminary amendment.	
14.	<input type="checkbox"/> A substitute specification.	
15.	<input type="checkbox"/> A power of attorney and/or change of address letter.	
16.	<input type="checkbox"/> Request for Deferred Examination.	
17.	<input checked="" type="checkbox"/> Application Data Sheet.	
18.	<input checked="" type="checkbox"/> Other items or information: Statement Under 37 C.F.R. § 1.821 (2 pgs.); Sequence Listing (26 pgs.); Sequence Diskette; IB308 (1 page); PCT/RO/101 (4 pages).	

13/535/72

RECEIVED 12 JUL 2006

Certificate of Mailing


Date of Deposit: July 12, 2006

Label Number: EV768765377US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De La Cruz

Printed name of person mailing correspondence


Signature of person mailing correspondence

APPLICATION
FOR
UNITED STATES LETTERS PATENT

APPLICANTS: Aiping H. YOUNG, Jim A. WRIGHT, and Yoon LEE

TITLE: ANTISENSE OLIGONUCLEOTIDES DIRECTED TO
RIBONUCLEOTIDE REDUCATASE R2 AND USES
THEREOF IN COMBINATION THERAPIES FOR THE
TREATMENT OF CANCER

11.000172

AP20 Rec'd PCT/PTO 12 JUL 2006

19. <input checked="" type="checkbox"/> The following fees are submitted:			
Basic National Stage Fee: \$300		\$300.00	
National Stage Search Fee		\$400.00	
Search fee (37 C.F.R. § 1.445(a)(2)) has been paid on the international application to the USPTO as an International Search Authority: \$100			
International Search Report prepared and provided to the Office: \$400			
All other situations: \$500			
National Stage Examination Fee		\$200.00	
If International preliminary examination report prepared by USPTO and all claims satisfied provisions of PCT Articles 33(1)-(4): \$100			
All other situations: \$200			
Surcharge of \$130 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)).		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	38 - 20 =	18	x \$50
			\$900
Independent claims	4 - 3 =	1	x \$200
			\$200
Multiple dependent claims (if applicable)		+ \$360	\$
Application Size Fee: Additional fee for specification and drawings in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.			
TOTAL SHEETS	EXTRA SHEETS	Number of each additional 50 sheets or fraction thereof (round up to a whole number)	RATE
-100=	/50=		X\$250
			\$250.00
TOTAL OF ABOVE CALCULATIONS =		\$2,250.00	
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status under 37 C.F.R. § 1.27		\$	
SUBTOTAL =		\$	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).		+	\$
TOTAL NATIONAL FEE =		\$ 2,250.00	
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property.		+	\$
TOTAL FEES ENCLOSED =		\$ 2,250.00	
		Amount to be refunded	\$
		charged	\$
<input checked="" type="checkbox"/> a. A check in the amount of \$2,250.00 to cover the above fees is enclosed. <input type="checkbox"/> b. Please charge my Deposit Account No. 03-2095 in the amount of \$ [**] to cover the above fees. <input checked="" type="checkbox"/> c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095.			
NOTE: Where an appropriate time limit under 37 C.F.R. §§ 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO:			
Kristina Bieker-Brady, Ph.D. Clark & Elbing LLP 101 Federal Street Boston, MA 02110-2214		Telephone: 617-428-0200 Facsimile: 617-428-7045 Customer No.: 21559	
		Signature Kristina Bieker-Brady, Ph.D. Reg. No. 39,109	

KAREN L. ELBING
 REG NO 35,238
 FOR